CXCR2 and neoplasm: The study exposed a previously unrecognized paradox where inhibiting Cxcl1-CXCR2 engagement invigorates T-cell activation while dampening tumor-wide TNF signaling, predominantly through disruption of MDSC-restricted TNF.